BR1100617A - Oligonucleotìdeo tendo seq id no: 22, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula, oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula compreendendo contactar a célula in vitro com um oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27 - Google Patents

Oligonucleotìdeo tendo seq id no: 22, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula, oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula compreendendo contactar a célula in vitro com um oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27

Info

Publication number: BR1100617A
Authority: BR; Brazil
Prior art keywords: oligonucleotide; sequence; cell; synthesis; adhesion molecules
Prior art date: 1990-08-14

Application number

BR1100617-0A

Other languages

English (en)

Inventor

C Frank Bennett

Christopher K Mirabelli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-08-14

Filing date

1997-05-13

Publication date

2000-06-13

1997-05-13 Application filed filed Critical

1997-05-13 Priority to BR1100617-0A priority Critical patent/BR1100617A/pt

2000-06-13 Publication of BR1100617A publication Critical patent/BR1100617A/pt

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 9
238000000034 method Methods 0.000 title abstract 5
102000016289 Cell Adhesion Molecules Human genes 0.000 title abstract 4
108010067225 Cell Adhesion Molecules Proteins 0.000 title abstract 4
230000015572 biosynthetic process Effects 0.000 title abstract 3
238000003786 synthesis reaction Methods 0.000 title abstract 3
238000000338 in vitro Methods 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
201000010099 disease Diseases 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
108020004414 DNA Proteins 0.000 abstract 1
108010024212 E-Selectin Proteins 0.000 abstract 1
102100023471 E-selectin Human genes 0.000 abstract 1
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 abstract 1
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 abstract 1
108091092195 Intron Proteins 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
108700009124 Transcription Initiation Site Proteins 0.000 abstract 1
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 1
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 1
230000021164 cell adhesion Effects 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000009396 hybridization Methods 0.000 abstract 1
230000004060 metabolic process Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
230000014621 translational initiation Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3531—Hydrogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Toxicology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Cell Biology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Storage Device Security (AREA)
Saccharide Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BR1100617-0A 1990-08-14 1997-05-13 Oligonucleotìdeo tendo seq id no: 22, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula, oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula compreendendo contactar a célula in vitro com um oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27 BR1100617A (pt)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
BR1100617-0A BR1100617A (pt)	1990-08-14	1997-05-13	Oligonucleotìdeo tendo seq id no: 22, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula, oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula compreendendo contactar a célula in vitro com um oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US56728690A	1990-08-14	1990-08-14
BR1100617-0A BR1100617A (pt)	1990-08-14	1997-05-13	Oligonucleotìdeo tendo seq id no: 22, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula, oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula compreendendo contactar a célula in vitro com um oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27

Publications (1)

Publication Number	Publication Date
BR1100617A true BR1100617A (pt)	2000-06-13

Family

ID=24266532

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BR919106746A BR9106746A (pt)	1990-08-14	1991-07-23	Oligonucleotideo ou analogo de oligonucleotideo e processos para modular a sintese de moleculas de adesao intracelular de adesao intracelular em um animal e para tratar um animal suspeito de ter uma doenca
BR1100617-0A BR1100617A (pt)	1990-08-14	1997-05-13	Oligonucleotìdeo tendo seq id no: 22, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula, oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula compreendendo contactar a célula in vitro com um oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BR919106746A BR9106746A (pt)	1990-08-14	1991-07-23	Oligonucleotideo ou analogo de oligonucleotideo e processos para modular a sintese de moleculas de adesao intracelular de adesao intracelular em um animal e para tratar um animal suspeito de ter uma doenca

Country Status (14)

Country	Link
EP (1)	EP0544716B1 (pt)
JP (1)	JP2732544B2 (pt)
KR (1)	KR960009261B1 (pt)
AT (1)	ATE230023T1 (pt)
AU (1)	AU641539B2 (pt)
BR (2)	BR9106746A (pt)
CA (1)	CA2089563C (pt)
DE (1)	DE69133180T2 (pt)
DK (1)	DK0544716T3 (pt)
ES (1)	ES2188581T3 (pt)
FI (1)	FI930627A0 (pt)
HU (1)	HU217107B (pt)
NO (1)	NO930513L (pt)
WO (1)	WO1992003139A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5827670A (en) *	1990-08-02	1998-10-27	Fred Hutchinson Cancer Research Center	Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US7449186B1 (en)	1990-08-02	2008-11-11	Fred Hutchinson Cancer Research Center	Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5789573A (en) *	1990-08-14	1998-08-04	Isis Pharmaceuticals, Inc.	Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
WO1993014769A1 (en) *	1992-01-31	1993-08-05	The Regents Of The University Of California	Method for making universal donor cells
IL101600A (en) *	1992-04-15	2000-02-29	Yissum Res Dev Co	Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US5596090A (en) *	1992-07-24	1997-01-21	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human VCAM-1 RNA
CA2143748A1 (en) *	1992-09-02	1994-03-17	C. Frank Bennett	Oligonucleotide modulation of cell adhesion
US6399376B1 (en) *	1993-11-05	2002-06-04	Isis Pharmaceuticals, Inc.	Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
DE4338704A1 (de)	1993-11-12	1995-05-18	Hoechst Ag	Stabilisierte Oligonucleotide und deren Verwendung
JPH08113591A (ja) *	1994-10-14	1996-05-07	Taiho Yakuhin Kogyo Kk	オリゴヌクレオチド及びこれを有効成分とする制癌剤
CA2223103A1 (en) *	1995-06-06	1996-12-12	Isis Pharmaceuticals Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
DE10019252A1 (de) *	2000-04-18	2001-10-31	Klaus Karl Degitz	Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression
CN104531843A (zh) *	2014-12-04	2015-04-22	杭州中翰金诺生物信息技术有限公司	肝癌诊断标志物黑素瘤细胞黏附分子及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989006702A1 (en) *	1988-01-21	1989-07-27	Chemex Pharmaceuticals, Inc.	Selective inhibition of gene expression by photoactivatable oligonucleotides
US5272263A (en) *	1989-04-28	1993-12-21	Biogen, Inc.	DNA sequences encoding vascular cell adhesion molecules (VCAMS)

1991
- 1991-07-23 ES ES91914455T patent/ES2188581T3/es not_active Expired - Lifetime
- 1991-07-23 DK DK91914455T patent/DK0544716T3/da active
- 1991-07-23 AU AU83130/91A patent/AU641539B2/en not_active Expired
- 1991-07-23 CA CA002089563A patent/CA2089563C/en not_active Expired - Lifetime
- 1991-07-23 HU HU9300373A patent/HU217107B/hu not_active IP Right Cessation
- 1991-07-23 EP EP91914455A patent/EP0544716B1/en not_active Expired - Lifetime
- 1991-07-23 WO PCT/US1991/005209 patent/WO1992003139A1/en not_active Ceased
- 1991-07-23 AT AT91914455T patent/ATE230023T1/de not_active IP Right Cessation
- 1991-07-23 BR BR919106746A patent/BR9106746A/pt not_active Application Discontinuation
- 1991-07-23 DE DE69133180T patent/DE69133180T2/de not_active Expired - Lifetime
- 1991-07-23 JP JP3513375A patent/JP2732544B2/ja not_active Expired - Lifetime
1993
- 1993-02-12 NO NO93930513A patent/NO930513L/no not_active Application Discontinuation
- 1993-02-12 FI FI930627A patent/FI930627A0/fi unknown
- 1993-02-15 KR KR93700438A patent/KR960009261B1/ko not_active Expired - Fee Related
1997
- 1997-05-13 BR BR1100617-0A patent/BR1100617A/pt active IP Right Grant

Also Published As

Publication number	Publication date
EP0544716A4 (en)	1994-09-14
HU217107B (hu)	1999-11-29
FI930627A7 (fi)	1993-02-12
EP0544716B1 (en)	2002-12-18
NO930513D0 (no)	1993-02-12
JP2732544B2 (ja)	1998-03-30
ES2188581T3 (es)	2003-07-01
DE69133180D1 (de)	2003-01-30
CA2089563A1 (en)	1992-02-15
KR960009261B1 (en)	1996-07-16
AU8313091A (en)	1992-03-17
BR9106746A (pt)	1993-07-20
HU9300373D0 (en)	1993-05-28
HUT68322A (en)	1995-06-28
CA2089563C (en)	2004-04-06
NO930513L (no)	1993-04-01
ATE230023T1 (de)	2003-01-15
FI930627A0 (fi)	1993-02-12
DE69133180T2 (de)	2003-07-24
WO1992003139A1 (en)	1992-03-05
AU641539B2 (en)	1993-09-23
DK0544716T3 (da)	2003-03-17
KR930701180A (ko)	1993-06-11
EP0544716A1 (en)	1993-06-09
JPH05508998A (ja)	1993-12-16

Legal Events

Date	Code	Title
1997-09-02	AN	Processing applications according to articles 230 and 231 of law 9279/96: notification of filing an application
1998-04-28	HHFK	Processing applications according to articles 230 and 231 of law 9.279/96: republication
2000-03-14	FGAN	Processing applications according to articles 230 and 231 of law 9.279/96: granting
2000-06-13	NB	Patent issued - articles 230 and 231 of law 9279/96

Publication	Publication Date	Title
AU690858B2 (en)	1998-04-30	Oligonucleotide modulation of cell adhesion
EP0527818A4 (en)	1993-09-15	Oligonucleotide modulation of arachidonic acid metabolism
Springer et al.	1994	Expression of GDNF mRNA in rat and human nervous tissue
EP0714449A4 (en)	1998-12-02	OLIGONUCLEOTIDE MODULATION BY PROTEIN KINASE
ATE244506T1 (de)	2003-07-15	Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
DE69331467D1 (de)	2002-02-21	Oligonukleotide modulation von protein kinase c
BR1100617A (pt)	2000-06-13	Oligonucleotìdeo tendo seq id no: 22, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula, oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula compreendendo contactar a célula in vitro com um oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27
BR9106440A (pt)	1993-05-18	Oligonucleotideo ou analogo de olifonucleotideo e processo para tratar um animal suspeito de ter uma doenca que se caracteriza pela expressao de gene tat de hiv
KR920702865A (ko)	1992-10-28	선경성장인자와 뇌유도성 향신경인자와 연관된 신규한 신경성 인자인 뉴트로핀-3(nt-3)
ATE318273T1 (de)	2006-03-15	Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
Pizzuti et al.	1990	Detection of β-nerve growth factor mRNA in the human fetal brain
Bennett et al.	1997	Oligonucleotide modulation of cell adhesion
NO924140L (no)	1992-12-11	Oligonukleotidmodulering av arachidonsyre-metabolisme